ANNAW Market Analysis

Fundamentals

Updated daily after market close
P/E ratio
EPS (TTM)-97.1% YoY
Profit margin23.8%
Market cap

Valuation

Forward P/E
PEG ratio
P/B
P/S (TTM)
EV/EBITDA

Profitability & growth

ROE (TTM)
17.7%
Operating margin
33.0%
Revenue growth YoY
1349.0%
Dividend yield
Beta
-1.63

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

About AleAnna, Inc. Warrant

Company profile

AleAnna, Inc. Warrant (ANNAW) is an innovative biopharmaceutical firm focused on creating transformational therapies for significant unmet medical needs. The company's strategic development includes a strong pipeline of proprietary drug candidates, supported by advanced technologies and collaborative partnerships within the healthcare industry. AleAnna is well-positioned for successful commercialization of its therapeutics, offering institutional investors a promising opportunity for growth in the rapidly evolving biopharmaceutical landscape. With its commitment to enhancing patient outcomes,…

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
300 CRESCENT COURT, DALLAS, TX
Fiscal year end
December
Latest quarter
Mar 31, 2026
Shares outstanding$0
52W high$1.28
52W low$0.12

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer